Posted by Michael Wonder on 16 Jul 2024
Sumitomo Pharma announces that DSP-5336 has received FDA fast track designation for the treatment of relapsed or refractory acute myeloid leukaemia
15 July 2024 - -- Sumitomo Pharma today announced that the US FDA granted fast track designation to DSP-5336 for the treatment of patients with relapsed or refractory acute myeloid leukaemia with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement or nucleophosmin mutation.
DSP-5336 is an investigational small molecule inhibitor of the menin and mixed lineage leukaemia protein interaction, which plays key roles in gene expression and protein interactions involved in many biological pathways, including cell growth, cell cycle, genomic stability, and haematopoiesis.
